BTIG initiated coverage of Hyperfine with a Buy rating and $2 price target. The company's Swoop System enables point-of-care brain MRI at the bedside, expanding access to MRI imaging by eliminating the need for a shielded room, specialized staff, and patient transport, and the next-generation Swoop V2, cleared in May 2025, paired with the 11th-generation Optive AI software release in December 2025, offers a significant step forward in image quality and clinical utility, the analyst tells investors in a research note.
